Dr. Peter Vu, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
200 W Arbor Dr
San Diego, CA 92103
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 127
Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A149741 (first issued 2017; current) -
Internal Medicine Physician
CA license A149741 (first issued 2017; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UC San Diego Health Hillcrest - Hillcrest Med Ctr San Diego, CA
Medical groups
- Regents of the University of California (2,089 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 127
- Services billed
- 941
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 348 | 93 |
| Established patient office or other outpatient visit, 30-39 minutes | 53 | 31 |
| Advance care planning, first 30 minutes | 34 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in San Diego, CA | 51 |
| Ondansetron Hcl Other prescribers in San Diego, CA | 39 |
| Oxycodone Hcl Other prescribers in San Diego, CA | 27 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in San Diego, CA | 21 |
| Gabapentin Other prescribers in San Diego, CA | 19 |
| Omeprazole Other prescribers in San Diego, CA | 17 |
| Eliquis (apixaban) Other prescribers in San Diego, CA | 17 |
| Enoxaparin Sodium Other prescribers in San Diego, CA | 16 |
| Creon (lipase/protease/amylase) Other prescribers in San Diego, CA | 12 |
| Lorazepam Other prescribers in San Diego, CA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $471 in total to this clinician.
| Saluda Medical Americas, Inc. | $311 |
|---|---|
| Biotronik Nro, Inc. | $133 |
| Amgen Inc. | $26.93 |
| Food and Beverage | $471 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $18,948 in research payments for these studies, mostly to the institutions running them.
- A P1,2 dose escal,expan to evaluate PYX-201 and Pembro in Adv solid tumors
Merck Sharp & Dohme LLC - A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06855771
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.